Evaluation of Trima Version 7.0 Platelets in 100% Plasma

The study is designed to evaluate changes to the Trima Accel software to ensure the modified
software meets the FDA acceptance criteria for leukoreduction and platelet yield. The
operating range for the system flow rates, anticoagulant ratios, storage conditions, and
centrifugal forces are the same as the currently cleared Trima Accel system. There are no
changes to the environment or storage conditions for platelets, therefore, no in vitro or in
vivo platelet quality data will be collected.

This is a prospective, open-label, multi-center controlled study to evaluate the
leukoreduction of platelets stored in 100% plasma collected on the Trima Accel system Version
7.0 software enhancement. Up to 350 healthy adult subjects will be enrolled in this study to
ensure 93 single, 93 double and 93 triple platelet product evaluable data points. Evaluable
is defined as a completed platelet product that does not meet any of the protocol analysis
exclusion criteria.

Plateletpheresis will be per site standard practice and per applicable FDA guidelines such as
the FDA Collection of Platelets by Automated Methods, December 2007 Guidance for Industry and
Pre-storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion,
September 2012.

Study participation will be up to 30 days and will consist of 1 to 2 visits. Screening may be
done within 30 days before the apheresis procedure or combined as a single visit, which
includes screening and the apheresis procedure all in 1 day.

The entire study should be completed in approximately 16 months.

Inclusion Criteria:

- Age 18 years or older.

- Meets the inclusion criteria defined by the Blood Center for an apheresis platelet
with plasma collection on the Trima Accel system. These criteria are based on FDA
guidance and the American Association of Blood Banks (AABB) standards. Note: subjects
who are deferred from volunteer community donations because of travel restrictions,
piercings, or tattoos may participate in the study, as products are not transfused.

- Has given written informed consent.

Exclusion Criteria:

- Has previously donated an evaluable platelet product in this study (CTS 5060).